Prothrombin Complex Concentrates Market

Prothrombin Complex Concentrates Market Outlook

The global prothrombin complex concentrates market is expected to be valued at USD 772.0 million in 2023 and reach a valuation of USD 1.2 billion by 2033. The demand for prothrombin complex concentrates is estimated to record a steady CAGR of 4.1%, with the United Kingdom, the United States., China, and India emerging as key producers.

In the prothrombin complex concentrates market, there is a growing focus on improving patient safety, with many companies aiming to create safer and more efficient products that have fewer side effects. This trend has resulted in the development of novel prothrombin complex concentrates products such as non-activated prothrombin complex concentrates and recombinant factor VIII products, which have proven to be more effective.

Personalized medicine is a growing trend in the prothrombin complex concentrates market, and companies are developing tailored products to address individual patient needs. This includes products made specifically for patients with different bleeding diseases and precision medications that aim to treat particular genetic abnormalities.

There is also a trend toward the development of innovative delivery methods for prothrombin complex concentrates, such as subcutaneous and intranasal delivery systems. These methods are preferred because they are more convenient and can enhance patient adherence to treatment.

To increase efficiency in prothrombin complex concentrates production and distribution, many companies are utilizing data analytics and digital technologies, including predictive analytics, to forecast demand, and digital tools to optimize supply chain management.

The potential for blood clots in prothrombin concentrate complex is one of the key factors limiting market growth. Blood clots can cause problems like venous thromboembolism, microvascular thrombosis, Disseminated Intravascular Coagulation (DIC), and myocardial infarction.

A market study called "Thromboembolic Events after Vitamin K Antagonist Reversal with 4-Factor Prothrombin Complex Concentrate" found that 7.3% of patients who got 4-factor- prothrombin complex concentrates had thromboembolic events.

Also, according to the UPMC System Pharmacy and Therapeutics Committee Formulary Evaluation, 2.9% of Kcentra users experienced thromboembolic events after using the medication. This raises safety concerns about employing factor IX complex goods, which is expected to probably impede the market.

Attributes	Details
Prothrombin Complex Concentrates Market CAGR (2023 to 2033)	4.1%
Prothrombin Complex Concentrates Market Size (2023)	USD 772.0 million
Prothrombin Complex Concentrates Market Size (2033)	USD 1.2 billion

What is the Prothrombin Complex Concentrates Future Outlook Compared to Historical Outlook?

The global demand for prothrombin complex concentrates recorded a CAGR of 4.4% between 2018 and 2022, and it's expected to record a CAGR of 4.1% between 2023 and 2033. The market's growth potential could be looked at from short-term, mid-term, and long-term perspectives.

Short Term Outlook (2023 to 2025)	As the global incidence of bleeding disorders continues to rise, there is a growing demand for effective and safe treatments. Prothrombin complex concentrates are becoming increasingly popular due to their ability to quickly reverse the effects of anticoagulant therapy, making them a valuable treatment option for patients with coagulation disorders.
Mid Term Outlook (2025 to 2028 )	Many companies are investing in research and development to create prothrombin complex concentrates and improve the efficacy and safety of existing products. This investment is expected to lead to the development of new treatments and an expansion of the market.
Long Term Outlook (2028 to 2032 )	The increasing availability of healthcare infrastructure in emerging markets such as India and China is creating growth opportunities for prothrombin complex concentrates. The approval of new prothrombin complex concentrates products in these markets can lead to significant growth for manufacturers.

Using Warfarin to Expand the Market Swiftly

Warfarin has become the most common oral anticoagulant for people with thrombosis. Anti-thrombotic medicine sales, including warfarin, account for around 3% of all drug sales globally and are anticipated to increase.

Fresh frozen plasma (FFP) and other therapies like it can't compete with Prothrombin Complex Concentrate.

A transfusion reaction and volume overload can occur when FFP and other therapies are used. Also, FFP is rarely able to bring the INR back to normal. Prothrombin complex concentrate, on the other hand, is an effective way to normalize the INR and reduce the risk of pathogen transmission.

Problems with clotting caused by Prothrombin Complex Concentrate

Blood clots can happen when prothrombin complex concentrate is given, leading to microvascular thrombosis, disseminated intravascular coagulation, and myocardial infarction. Underlying illnesses, excessive dosages of prothrombin complex concentrate, and unbalanced ingredients can all increase the risk of thrombotic problems.

Unmet Hemophilia Therapeutic Needs and Growing Geriatric Population

As the requirement for anticoagulation therapy with oral anticoagulants is increasing amongst the geriatric population, the need to reverse anticoagulation in adverse conditions is also increasing. Thus, the growing geriatric population is expected to fuel the growth of the prothrombin complex concentrates market over the forecast period.

The worldwide incidence of hemophilia is not well known; however, it has been estimated that more than 400,000 people have hemophilia. 75% of people with hemophilia have been estimated to receive inadequate treatment or have no access to treatment.

80% Revenue Contribution by Leading Manufacturers in Prothrombin Complex Concentrates Market

The prothrombin complex concentrates global manufacturers mainly dominate the market. The manufacturers of prothrombin complex concentrates are competing based on the adoption of prothrombin complex concentrates. The growing demand for optimized & sustainable healthcare has created immense growth opportunities for global manufacturers.

Companies such as Shire, Octapharma AG, and CSL Behring GmbH hold approximately 80% revenue share in the global prothrombin complex concentrates market. Also, companies operating in the market are collaborating with retailers and local distributors to increase the penetration of prothrombin complex concentrates.

Country-wise Insights

Why is China Considered to be a Lucrative Prothrombin Complex Concentrates Market?

According to the discussions held with key opinion leaders in the prothrombin complex concentrates market, substantial growth has been witnessed in the China market for prothrombin complex concentrates.

Manufacturers operating in the China and APEC markets are estimated to have significant growth opportunities in the prothrombin complex concentrates market over the forecast period.

How is the United States Prothrombin Complex Concentrates Market Faring?

The United States prothrombin complex concentrates market is one of the significant and most established markets for prothrombin complex concentrates globally, and it continues to experience growth due to various factors.

One significant factor driving growth in the United States prothrombin complex concentrates market is the increasing incidence of bleeding disorders, such as hemophilia and von Willebrand disease.

According to the Centers for Disease Control and Prevention (CDC), hemophilia affects approximately 20,000 people in the United States, while von Willebrand disease affects 1% of the United States population. As the incidence of these disorders continues to rise, the demand for prothrombin complex concentrates is also increasing.

The growing use of prothrombin complex concentrates in emergency medicine is another factor boosting market expansion in the United States. Prothrombin complex concentrates products are commonly used in emergencies to treat patients with acute bleeding or coagulation disorders.

The availability of prothrombin complex concentrates in emergency departments, and trauma centers across the United States have led to a significant increase in demand for prothrombin complex concentrates.

Can India Become a Successful Market?

India has the potential to become a profitable market for prothrombin complex concentrates due to several factors, although challenges need to be addressed to achieve maximum potential.

One of the significant factors that make India attractive is its significant population which results in a substantial number of patients with coagulation disorders, including an estimated 450,000 hemophilia patients, which is one of the maximum numbers globally.

The demand for prothrombin complex concentrates is expected to grow as bleeding disorders increase. India's healthcare infrastructure is another appealing factor that has improved due to the Indian government's various initiatives, leading to an increase in healthcare facilities, including specialized treatment centers for bleeding disorders.

Accessibility to prothrombin complex concentrates has improved, creating market growth opportunities.

Also, due to the increasing awareness of bleeding disorders among patients and healthcare professionals, diagnosis and treatment rates have increased, creating a significant demand for prothrombin complex concentrates as patients and physicians seek more effective and safer treatment options.

Category-wise Insights

The market is expected to be led by the Hospitals & ASCs segment

Hospitals, outpatient surgical centers, specialized clinics, and other places make up the different segments of the market. For the next five years, the market's leadership is anticipated to rest with hospitals and the outpatient surgery segment.

This results from the COVID-19 pandemic-related increase in the use of prothrombin complex concentrate, government recommendations, and hospital purchases of more plasma products. The specialty clinics segment is likely to grow because some multiple surgeons and clinics are privately owned.

The others segment, which includes urgent care centers, emergency trauma centers, doctors' offices, and so on, is likely to grow because the government and private players are investing more in improving healthcare facilities.

The section on acquired coagulation factor insufficiency is anticipated to grow as more warfarin-related bleeding incidents occur.

Based on its use, the market is divided into two categories: congenital and acquired coagulation factor deficiency. The most lucrative market in 2019 was for acquired coagulation factor deficiency, and in the coming years, it is anticipated to expand rapidly.

The segment is expected to grow because there are more cases of life-threatening bleeding linked to the use of warfarin, more cases of induced coagulation factor deficiency during surgery, and new products.

According to the Hemophilia Federation of America, there are about 29,000 cases of bleeding in the United States each year that are caused by taking warfarin. This is expected to make this market segment grow rapidly by 2027.

The segment is also going to benefit significantly from the growing Kcentra sales brought on by the COVID-19 situation. On the other hand, government initiatives to find novel treatments for bleeding disorders like Hemophilia B are likely to benefit the congenital coagulation factor deficiency segment.

Competition Landscape

Companies are using various strategies to expand their market share. These include

• Strategic partnerships and collaborations: Many companies are forming partnerships and collaborations with other companies to expand their market reach, develop new products, and improve their manufacturing capabilities. For example, in 2021, Sanquin and Octapharma entered into a long-term partnership to develop and manufacture prothrombin complex concentrates on treating bleeding disorders.
• Product differentiation and innovation: Many companies focus on developing new and innovative prothrombin complex concentrates that offer better efficacy, safety, and patient convenience. For example, in 2020, CSL Behring received FDA approval for its Idelvion product, a longer-acting factor IX therapy that can be administered less frequently than traditional prothrombin complex concentrates.
• Market expansion: Many companies focus on expanding their market reach into emerging markets such as India, China, and Latin America. For example, in 2020, Grifols opened a new plasma fractionation plant in China to increase its regional presence and expand its prothrombin complex concentrates product offerings.
• Mergers and acquisitions: Many companies are using mergers and acquisitions to consolidate their position in the market, expand their product offerings, and gain access to new markets. For example, in 2021, Takeda announced its intention to acquire the biotech company, Maverick Therapeutics, to expand its oncology and hematology portfolios.

Key Segments

By Distribution Channel:

• Compound Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

By Region:

• North America
• Latin America
• Europe
• APEJ
• Middle East & Africa (MEA)

Frequently Asked Questions

What is the Current Prothrombin Complex Concentrates Market Size in 2023?

The market is estimated to acquire USD 772 million in 2023.

What Restrains the Prothrombin Complex Concentrates Market Growth?

PCC-related thrombotic complications restrain market growth.

What Fuels China’s Prothrombin Complex Concentrates Market?

Manufacturers operating in China increase significant growth opportunities in the market.

How is the United States Prothrombin Complex Concentrates Market Faring?

The increasing incidence of bleeding disorders raises the market.

What was the Last Four Years’ Growth Rate for Prothrombin Complex Concentrates?

The global market expanded at a CAGR of 4.4% between 2018 and 2022.